Hodgkin’s Lymphoma | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2016
The Hodgkin’s Lymphoma therapy market—currently dominated by multidrug chemotherapy regimens—will experience significant growth over the 2015-2025 forecast. This growth will be fueled by the label expansion of Adcetris and the approval of two immune checkpoint inhibitors, Opdivo (nivolumab) and Keytruda (pembrolizumab).
CONTENT OVERVIEW
From disease basics to insightful analysis of market dynamics, Hodgkin’s lymphoma | Disease Landscape & Forecast | US and EU5 provides comprehensive disease coverage addressing critical aspects of the Hodgkin’s lymphoma pharmaceutical market based on primary and secondary market research. Content pillars include a summary of disease etiology, pathophysiology, and drug targets; annualized epidemiological projections, including estimates of diagnosis and/or drug-treatment; a deep examination of current therapies and medical practice; a review of top unmet needs; a thorough pipeline assessment, including launch timing, positioning, and peak sales of key late-phase drugs; a topline review of pertinent market access themes; and an epidemiology-based, bottom-up market forecast with supporting tables, figures, and methods.
WHAT YOU WILL LEARN IN THIS CONTENT
- How large is the drug-treatable Hodgkin’s lymphoma population and how will drug-treatment rates change over time?
- What is the current state of treatment in Hodgkin’s lymphoma? Which are the most important drugs and why? What are interviewed experts’ insights on current treatment options? What clinical needs remain unfulfilled?
- What pipeline products are most promising, and what sales/uptake could they secure in Hodgkin’s lymphoma? What therapies of note are progressing in earlier phases?
- What are the drivers and constraints in the Hodgkin’s lymphoma market, and how will the market evolve over the forecast period?
KEY DRUGS COVERED
Adcetris, Opdivo, Keytruda, Farydak, Rituxan/MabThera
KEY COMPANIES MENTIONED
- Seattle Genetics
- Takeda
- Bristol-Myers Squibb
- Merck & Co.
- Novartis
- Roche/Genentech
